Kopp Family Office LLC Reduces Holdings in Viridian Therapeutics, Inc. $VRDN

Kopp Family Office LLC lowered its stake in shares of Viridian Therapeutics, Inc. (NASDAQ:VRDN) by 68.1% during the 1st quarter, HoldingsChannel.com reports. The fund owned 55,295 shares of the company’s stock after selling 117,878 shares during the quarter. Viridian Therapeutics accounts for about 0.7% of Kopp Family Office LLC’s holdings, making the stock its 16th biggest holding. Kopp Family Office LLC’s holdings in Viridian Therapeutics were worth $1,082,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Hudson Bay Capital Management LP raised its stake in shares of Viridian Therapeutics by 46.6% in the third quarter. Hudson Bay Capital Management LP now owns 175,251 shares of the company’s stock worth $3,782,000 after purchasing an additional 55,689 shares during the last quarter. Fisher Asset Management LLC boosted its position in Viridian Therapeutics by 135.6% in the third quarter. Fisher Asset Management LLC now owns 1,201,226 shares of the company’s stock valued at $25,922,000 after buying an additional 691,267 shares during the last quarter. Propel Bio Management LLC acquired a new position in Viridian Therapeutics in the 3rd quarter worth approximately $1,942,000. Jennison Associates LLC acquired a new position in Viridian Therapeutics in the 4th quarter worth approximately $35,915,000. Finally, Knott David M Jr raised its position in Viridian Therapeutics by 27.4% during the 3rd quarter. Knott David M Jr now owns 116,574 shares of the company’s stock worth $2,516,000 after buying an additional 25,091 shares during the last quarter.

Viridian Therapeutics Stock Up 0.2%

Shares of VRDN stock opened at $17.32 on Thursday. Viridian Therapeutics, Inc. has a twelve month low of $13.18 and a twelve month high of $34.29. The stock has a market cap of $1.79 billion, a P/E ratio of -5.22 and a beta of 0.90. The stock has a 50 day moving average of $16.15 and a 200 day moving average of $24.41. The company has a current ratio of 15.15, a quick ratio of 15.15 and a debt-to-equity ratio of 0.10.

Viridian Therapeutics (NASDAQ:VRDN) last released its quarterly earnings data on Tuesday, May 5th. The company reported ($0.90) EPS for the quarter, topping the consensus estimate of ($1.06) by $0.16. The business had revenue of $0.14 million for the quarter, compared to analyst estimates of $0.04 million. Viridian Therapeutics had a negative return on equity of 80.19% and a negative net margin of 490.31%.The business’s quarterly revenue was up 95.8% compared to the same quarter last year. During the same quarter in the prior year, the firm posted ($0.87) EPS. As a group, sell-side analysts expect that Viridian Therapeutics, Inc. will post -3.87 EPS for the current year.

Insider Transactions at Viridian Therapeutics

In other news, Director Fairmount Funds Management Llc purchased 1,176,470 shares of the stock in a transaction that occurred on Monday, May 11th. The shares were purchased at an average cost of $17.00 per share, with a total value of $19,999,990.00. Following the completion of the acquisition, the director owned 5,090,928 shares of the company’s stock, valued at approximately $86,545,776. This represents a 30.05% increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Company insiders own 2.40% of the company’s stock.

Wall Street Analysts Forecast Growth

VRDN has been the subject of several research reports. Truist Financial decreased their price objective on shares of Viridian Therapeutics from $36.00 to $33.00 and set a “buy” rating for the company in a research note on Tuesday, April 21st. Stifel Nicolaus set a $39.00 price objective on shares of Viridian Therapeutics in a research note on Wednesday, May 13th. HC Wainwright reduced their target price on shares of Viridian Therapeutics from $34.00 to $22.00 and set a “buy” rating for the company in a report on Tuesday, March 31st. Wells Fargo & Company decreased their target price on shares of Viridian Therapeutics from $29.00 to $20.00 and set an “equal weight” rating for the company in a research report on Tuesday, March 31st. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Viridian Therapeutics in a report on Monday, April 20th. Twelve research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $36.14.

About Viridian Therapeutics

Viridian Therapeutics, Inc (NASDAQ: VRDN) is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted antibody therapeutics for patients suffering from rare and serious diseases. The company’s lead program, VRDN-001, is a fully human monoclonal antibody that antagonizes the insulin-like growth factor-1 receptor (IGF-1R), with an initial focus on thyroid eye disease (TED). By selectively inhibiting IGF-1R signaling, VRDN-001 aims to reduce inflammation and tissue remodeling associated with TED and related disorders.

In addition to VRDN-001, Viridian is advancing a second antibody program, VRDN-002, which targets complement-mediated pathways implicated in autoimmune and inflammatory diseases.